Spin Pharma exists to make the future of medicine exciting and understandable — without ever confusing a promising experiment with a proven treatment.
We cover biotech, pharmaceuticals, medical technology, AI, genomics, cell health, longevity, cancer research, startups and the public companies shaping these fields. Think of us as the meeting point between a science magazine, a biotech intelligence dashboard and an interactive learning lab.
Who we write for
- Curious readers who want the story behind the headline.
- Patients and families looking for general education — never personal medical advice.
- Founders and researchers tracking what is moving and why.
- Students learning the language of modern medicine.
- Investors who want the science explained separately from the share price.
The Spin
Every major story carries The Spin: five straight answers to What happened? What does the evidence actually show? What is still uncertain? Who or what could be affected? What should we watch next?
How we label evidence
Each article states its evidence stage — preclinical, clinical, approved, mixed overview or speculative — and its intended audience. We link to primary research, trial records and regulators, and show when each article was published and last reviewed. Read our editorial standards and disclosures.
Who we are
Spin Pharma is published by Mass Density, Inc. of Doral, Florida. Questions, tips or corrections: contact us.
The Spin Brief
One concise weekly roundup of what moved in medicine — what happened, what the evidence shows, and what to watch next. No hype, no stock tips.
- Five stories that mattered, each with its own Spin
- One stage change in the pipeline tracker, sourced
- One Lab question to think about
We use double opt-in: check your inbox to confirm. We never sell your address, and we never ask for health or genetic information.